Published in J Diabetes Investig on June 01, 2010
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig (2013) 1.55
Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) (2013) 1.23
Renal protective effects of resveratrol. Oxid Med Cell Longev (2013) 0.99
Epigenetic modifications and diabetic retinopathy. Biomed Res Int (2013) 0.97
Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. Middle East Afr J Ophthalmol (2015) 0.88
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. Diabetes (2016) 0.83
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications. J Diabetes Res (2015) 0.82
Consumption of Polyphenol-Rich Zingiber Zerumbet Rhizome Extracts Protects against the Breakdown of the Blood-Retinal Barrier and Retinal Inflammation Induced by Diabetes. Nutrients (2015) 0.81
Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. J Clin Biochem Nutr (2016) 0.81
The association of normal range glycated hemoglobin with restrictive lung pattern in the general population. PLoS One (2015) 0.78
Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol (2015) 0.77
p21(WAF1/CIP1) Expression is Differentially Regulated by Metformin and Rapamycin. Int J Chronic Dis (2014) 0.76
Interventions against nutrient-sensing pathways represent an emerging new therapeutic approach for diabetic nephropathy. Clin Exp Nephrol (2013) 0.76
Potential Role of Protein Disulfide Isomerase in Metabolic Syndrome-Derived Platelet Hyperactivity. Oxid Med Cell Longev (2016) 0.75
Association of prediabetes-associated single nucleotide polymorphisms with microalbuminuria. PLoS One (2017) 0.75
On the Environmental Factors Affecting the Structural and Cytotoxic Properties of IAPP Peptides. J Diabetes Res (2015) 0.75
Nailfold capillary abnormalities are associated with type 2 diabetes progression and correlated with peripheral neuropathy. Medicine (Baltimore) (2016) 0.75
Conditioned Medium from Early-Outgrowth Bone Marrow Cells Is Retinal Protective in Experimental Model of Diabetes. PLoS One (2016) 0.75
Assessment of the cardiovascular and gastrointestinal autonomic complications of diabetes. World J Diabetes (2016) 0.75
The Diabetes Visual Function Supplement Study (DiVFuSS). Br J Ophthalmol (2015) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev (2007) 21.13
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 16.24
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 12.33
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 12.18
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (1997) 10.54
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med (2003) 5.87
The cytoprotective protein C pathway. Blood (2006) 5.75
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes (2000) 4.55
Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia (1983) 4.48
Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med (2009) 4.26
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA (2002) 4.18
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Structural basis of protein kinase C isoform function. Physiol Rev (2008) 4.00
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 3.83
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol (2008) 3.83
Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol (1961) 3.80
Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest (2000) 3.79
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
The changing natural history of nephropathy in type I diabetes. Am J Med (1985) 3.50
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest (2001) 3.46
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A (2000) 3.36
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest (1999) 3.18
Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem (1999) 3.12
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes (1997) 3.08
Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 2.93
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab (2001) 2.91
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 2.80
Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J (2002) 2.73
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Hyperglycemic pseudohypoxia and diabetic complications. Diabetes (1993) 2.62
Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A (1992) 2.48
Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab (2007) 2.48
Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol (1997) 2.45
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci U S A (1997) 2.42
Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem (2001) 2.42
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int (2007) 2.39
Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res (2002) 2.37
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med (2009) 2.31
Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia (2008) 2.26
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. Circulation (2000) 2.18
VEGF(165) mediates glomerular endothelial repair. J Clin Invest (1999) 2.18
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 2.16
Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol (2007) 2.13
Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab (2006) 2.12
Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A (1991) 2.12
The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest (2003) 2.11
Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation (2009) 2.09
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest (2001) 2.07
The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res (2007) 2.06
Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A (1993) 2.00
Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J (2000) 1.93
Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab (2003) 1.92
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 1.92
Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol (2001) 1.90
Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol (2007) 1.80
Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol (2003) 1.79
Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol (2001) 1.75
Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest (1997) 1.75
Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes (2006) 1.71
Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes (1999) 1.70
Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes (2002) 1.67
Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem (2000) 1.67
Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest (1994) 1.63
Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int (2007) 1.63
O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci U S A (2001) 1.60
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int (2006) 1.59
Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes (1991) 1.58
Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology (2006) 1.54
Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol (2001) 1.54
Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis (2004) 1.53
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 1.51
Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem (1994) 1.47
O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol (1997) 1.47
Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care (2007) 1.46
Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol (2005) 1.43
Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med (1994) 1.42
VEGF localisation in diabetic retinopathy. Br J Ophthalmol (1998) 1.40
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care (2002) 1.40